Galapagos, Roche enter three-year collaboration

By Lisa Kerner

Erie, Pa., March 28 - Galapagos NV said its service division, BioFocus, has entered into a three-year collaboration with Roche whereby BioFocus will supply Roche with exclusive chemical compound libraries.

Financial terms were not disclosed, according to a company news release.

BioFocus designs and synthesizes chemical compound libraries used in drug discovery programs, including hit finding, lead optimization and patent exemplification, the release stated.

"We are very pleased with this new agreement to deliver exclusive compound libraries to complement Roche's drug discovery programs," Galapagos chief executive officer Onno van de Stolpe said in the release.

"With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries."

Galapagos is a publicly traded, genomics-based drug discovery company located in Mechelen, Belgium. The company offers target-to-drug discovery products and services to pharmaceutical and biotech companies through BioFocus.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.